Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Infusion set Stories

2013-08-22 12:28:14

New Six-Year Contract Marks the First Time Needlefree Connectors Are Contracted Separately from IV Pumps and Solutions by a Major GPO, Allowing Premier Member Hospitals Greater Freedom to Make Decisions Based on Patient Safety SAN CLEMENTE, Calif., Aug. 22, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) today announced that it has received two separate six-year group purchasing contracts from the Premier healthcare alliance covering the company's complete line of...

2013-04-17 08:30:11

Agreement brings the only non-magnetic MRI IV pump currently available on the U.S. market to more than 1,400 new customers WINTER PARK, Fla., April 17, 2013 /PRNewswire/ -- HealthTrust Purchasing Group (HealthTrust), one of the largest health care supply contracting companies in the United States, has awarded IRadimed Corporation a contract for its MRidium(TM) MRI Infusion Pump Systems. Effective April 1, 2013, the agreement makes the MRidium(TM) Systems available to the more...

2013-03-08 12:25:29

OTTAWA, March 8, 2013 /CNW/ - Health Canada is informing Canadians and Canadian health care practitioners that Hospira Inc., a drug and medical device manufacturer, is voluntarily stopping all new sales of its intravenous infusion pumps while it addresses issues in its quality management system. Health Canada is monitoring Hospira's actions to resolve any quality, safety and effectiveness issues related to its infusion pumps sold in Canada and will take corrective action necessary...

2012-06-09 06:21:34

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented results from a Phase 4 study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. Interim data from this study indicate that pre-administration of Hylenex recombinant in the SAP provided a consistent ultrafast insulin action profile over the infusion set life that resulted in improved glucose...

2012-06-09 06:21:30

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) Presenters will be available to discuss the posters at the...

2012-06-04 02:25:44

WINTER PARK, Fla., June 4, 2012 /PRNewswire/ -- Novation, the largest health care supply contracting company in the United States, has awarded IRadimed Corporation a three-year single source contract for its MRidium(TM) MRI Infusion Pump Systems. Effective September 1st, 2012, the agreement makes the MRidium(TM) Systems available to all 65,000 VHA, UHC and Provista members served by Novation. MRidium was awarded the contract under Novation's MR Compatible IV Pump category. This new agreement...

2012-03-12 07:44:00

WINTER PARK, Fla., March 12, 2012 /PRNewswire/ -- The Premier healthcare alliance has awarded IRadimed Corporation a three-year contract for its MRidium(TM) MRI Infusion Systems. Effective January 1st, 2012, the agreement makes the MRidium(TM) Systems available to Premier members. There are more than 2,500 U.S. hospitals and 81,000-plus other healthcare sites in the Premier alliance. MRidium was awarded the contract under Premier's MR Compatible Equipment Category which includes MRI Infusion...

2011-10-27 18:05:00

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from a study in patients with type 1 diabetes that receive their insulin therapy via pumps. The Phase 1b study was conducted as a randomized, double-blind, crossover design, to determine insulin...

2011-07-18 11:40:00

BETHLEHEM, Pa., July 18, 2011 /PRNewswire/ -- In an effort to expand its offerings for infusion therapy in both the acute care hospital and outpatient markets, with an initial focus on home infusion, B. Braun Medical Inc. (B. Braun) announced today an exclusive alliance with CME America to distribute the BodyGuard® line of electronic infusion pumps. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO ) The five-year exclusive distribution agreement allows B....

2011-06-24 16:01:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone. Halozyme is...